Market Research Blog – Page 9102 – New Product Development

Frozen Egg Market Research on Present State and Future Growth Prospects of Key Players, Forecast by 2022-2032

The global frozen egg market is expected to reach a market valuation of US$ 3.8 Bn by the year 2022, accelerating with a CAGR of 6.7% by 2022-2032. Frozen egg sales currently account for about ~6.2% of the global egg market in terms of value.

Frozen egg products are becoming increasingly popular in the catering industry. Private cafeterias in colleges, healthcare facilities, and commercial enterprises are observing how frozen egg products can be used to replace daily meals. Parallel to the ever-changing landscape of the food and beverage industries, consumers’ proclivity for frozen products is changing. In the near future, it is expected that a large consumer base will gravitate toward less perishable egg-based products instead of fresh eggs.

Frozen Egg Market Size (2022E)	USD 3.8 Bn
Frozen Egg Market Projected Size (2032F)	USD 7.2 Bn
Value CAGR (2022-2032)	6.7%
Top 3 Countries Market Share	39.6%

The growing consumer preference for foods that require little preparation and serve quickly has reduced the demand for fresh egg items in institutional food services. Simultaneously, sales for frozen egg products in food service services has increased, especially among working professionals who prefer frozen eggs, especially frozen egg whites.

Request a report sample to gain comprehensive insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-14338

Key Takeaways from Market Study

The frozen eggs market is estimated to expand at CAGRs of 6.7% over the forecasted period
The Europe frozen eggs market is currently holding around 26.2% of value share in 2022.
Among product types in the frozen eggs market, the whole eggs account for around 60% of market share, followed by egg white types.
China holds more than 55.3% of market share in East Asia and expected to grow with 9.3% over forecast period
Germany, France, Italy, Spain, UK are key consumers of frozen eggs in European Country.

“Manufacturers of frozen eggs products would achieve impressive growth by targeting the functional food and beverages industry. Demand for Immunity boosting products has been on the rise following COVID-19 outbreak. These products are playing crucial role in one’s life, hence targeting that segment of functionality will impact the market positively”, says a Future Market Insights analyst.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-14338

Competitive Landscape

Key manufacturers are also evolving with recyclable wrapping solutions in order to meet ecofriendly rules plus to gain traction of consumers. Technological invention in packaging approaches can lift product sales expressively, as it develops product quality to a superior extent.

NestFresh, a leader in local, humane, and sustainable eggs, acquired New Barn Organics in 2021, expanded its presence into the globe of feasible and humane food.

NestFresh, the chief in processed eggs, demonstrated its categorization leadership once more in 2020 with the introduction of a brand’s new EGG POP.

Explore More Valuable Insights

Future Market Insights, in its new report, offers an impartial analysis of the global Frozen eggs market, presenting historical data (2017-2021) and estimation statistics for the forecast period of 2022-2032.

Frozen Egg Market by Category

By Product Type, Frozen Egg Market is segmented as:

Whole Eggs
Egg Whites
Egg Yolk

By End-use Application, Frozen Egg Market is segmented as:

Food Processing Industry
- Bakery & Confectionery
- Creamy Sauces
- Ice-cream & Frozen Desserts
- Mayonnaise
- Noodles & Pasta
- Salad Dressings
- Others
Food Service Providers
Retail/Household
- Convenience Stores
- Discount Stores
- Modern Trade
- Grocery Stores
- Online Retail
- Specialty Stores
- Wholesalers
- Other Sales Channel

By Region, Frozen Egg Market is segmented as:

North America
Latin America
Europe
East Asia
South Asia
Oceania
The Middle East and Africa

The report covers exhaustive analysis on:

How big is the frozen egg market?
What is the anticipated market value of the frozen egg market by 2032 end?
What is the frozen egg market outlook?
Which region is expected to drive the demand for the frozen egg market?
Who are the key players operating in the market?

To remain ‘ahead’ of your competitors, get customized report : https://www.futuremarketinsights.com/customization-available/rep-gb-14338

Download complimentary copy of Future Market Insights White Paper in collaboration with PBFIA, on the Plant Based Market that throws light on potential opportunities and investments made in the Global plant based market

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

Browse latest Market Reports: https://www.futuremarketinsights.com/reports

LinkedIn| Twitter| Blogs

Egg Substitute Market Trends 2022-2032: Why Now Is the Most Relevant Time for Your Own Product?

The egg substitute market is expected to reach US$ 1.1 Bn in 2022. With sales growing at a 5.9% CAGR, the market valuation will reach US$ 2.1 Bn in 2032. Increasing preference for natural ingredients in packaged food and bakery products is expected to drive sales in the market. Egg substitutes can be used in place of eggs in recipes and baked goods. They are primarily preferred by vegans, however, they are occasionally preferred by others seeking variation in taste.

Egg Substitute Market Estimated Size in 2022	US$ 1.1 Bn
Egg Substitute Market Projected Size in 2032	US$ 2.1 Bn
Egg Substitute Market Value-based CAGR (2022 to 2032)	5.9% CAGR
Egg Substitute Market Collective Value Share: Top 3 Countries (2022)	33.6%

The usage of egg substitutes has no effect on the taste or appearance of the finished product. Surging application of egg substitutes in numerous products such as mayonnaise, chocolates, ice cream, custard, cakes, muffins, biscuits, and other baked goods is propelling the market.

These substitutes are as beneficial as eggs in terms of nutrition, being cholesterol-free, gluten-free, and high in vitamins A and B12, among other nutrients. Increasing awareness regarding the nutritional benefits of egg substitutes, as well as the inclination to eat healthy food items, are complementing the growth in the market.

“Key manufacturers are investing in branding and product labelling to boost sales of egg substitutes. Besides this, increasing adoption of egg substitutes in nutraceuticals and dietary supplements is expected to boost the market in the forthcoming years,” says an FMI analyst

To remain ‘ahead’ of your competitors, request for @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14323

Key Takeaways:

Based on form, the liquid segment is anticipated to account for around 46.7% of the total market share over the forecast period.
The North America egg substitute market is expected to expand at a 5.6% CAGR through 2032.
Sales in the East Asia egg substitute market are forecast to account for 18.9% of the global egg substitute consumption through 2032.
Egg substitute application in the bakery industry is expected to hold a market share of over 41.5% over the forecast period.

Competitive Landscape

Some of the prominent players of the global egg substitute market include Corbion, DuPont Nutrition & Health, Kerry Group, Florida Food Products, Glanbia Plc, MGP Ingredients, Archer Daniels Midland Company, Tate and Lyle and Ingredion Inc., Ingredion Incorporated, Cargill Inc., LLC Fiberstar Inc., and Others

For Information On The Research Approach Used In The Report, Ask Analyst @

https://www.futuremarketinsights.com/ask-question/rep-gb-14323

Explore More Valuable Insights

Future Market Insights, in its new report, offers an impartial analysis of the global Egg Substitute market, presenting historical data (2017-2021) and estimation statistics for the forecast period of 2022-2032.

The study offers compelling insights based on the egg substitute market

Egg Substitutes Market By Category

Form :

Dry
Liquid

Source :

Plant
Animal

Ingredient :

Dairy Proteins
Starch
Algal Flour
Soy-based Products

Application :

Bakery & Confectionery
Savories
Sauces
Dressings & Spreads

Distribution Channel :

Convenience Stores
Hypermarkets
Departmental Stores
Others

Region :

North America
Europe
Asia-Pacific
Latin America
Middle East & Africa

We Offer tailor-made Solutions to fit Your Requirements, Request Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-14323

The report covers exhaustive analysis on:

How much is the egg substitute market currently worth?
What was the last 5-year CAGR for the egg substitute market?
What will be the next 10-year CAGR for the egg substitute market?
What is the share of top 5 players in the egg substitute market?
Who are the top 5 countries driving egg substitute market?
At what rate will the egg substitute market increase in North America?
What is the Latin America egg substitute market outlook?
What is the market outlook for egg substitute in EMEAI region?
At what rate did the egg substitute market increase between 2021 and 2022?

About Future Market Insights (FMI)

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

Browse latest Market Reports: https://www.futuremarketinsights.com/reports

LinkedIn| Twitter| Blogs

Titanium Dioxide Color Market with Supply Chain Analysis and Examine of Mid-Level Participant with Packaging Type-2022-2032

The titanium dioxide color market is expected to reach US$ 31.6 Mn in 2022. The overall market value is expected to reach US$ 42.1 Mn by the end of 2032, exhibiting growth at a CAGR of 2.9% during the forecast period (2022-2032).

Titanium dioxide color, being cost-effective, is used in many dairy-based products, such as cheese, ice cream, milk drinks & milk alternatives, pudding / custard, dips & spreads and yogurt.

More expensive dairy solids as colorant may be replaced by the product as to reduce calories and fat content, as consumers are inclined towards tasty food products nowadays but more with a health-conscious objective.

In terms of application, the dairy segment is projected to expand at a CAGR of 2.4% over the forecast period, exceeding US$ 1,835.0 Thousand in 2022.

Click the link to get a Sample Copy of the Report @
https://www.futuremarketinsights.com/reports/sample/rep-gb-14299

Key Takeaways from Titanium Dioxide Color Market Study:

The U.S. is estimated to account for more than 87.3% of the North America market in 2022 for titanium dioxide color.
Brazil is projected to lead the Latin America titanium dioxide color market with 47.7% market share in 2022.
Latin America is anticipated to register highest CAGR of 4.4% during the forecast period backed by growing consumer awareness regarding the use of the product.
EMEAI region is projected to hold highest market value with US$ 14,487.6 Thousand in 2022.
Germany is estimated to account for 21.8% of EMEAI market share in 2022, while India is estimated to hold over 14.6% share in Asia Pacific.
China is projected to hold market share of 40.3% in APAC in 2022.

Who is winning?

Key players are focusing primarily on growth drivers for titanium dioxide color market, as the growing demand for the product among consumers in end use food industries are rising with each passing day. Manufacturing processes of the powder form product with technological innovations are improving day by day, thus increasing the product yield with higher quality. This is also expected to have a positive impact on the product quality, thus aiding the titanium dioxide color market growth.

Some of the leading companies offering titanium dioxide color are Tronox Incorporated, DuPont, Huntsman, Evonik Industries, Millennium Chemicals, Kronos, Ishihara Sangyo Kaisha Ltd., The Chemours Company, Lomon Billions Group and others.

Ask Our Analyst More about Report @
https://www.futuremarketinsights.com/ask-question/rep-gb-14299

Titanium Dioxide Color by Category

By Application:

Beverage
Bakery, Snacks, & Cereal
Candy / Confectionery
Dairy
Fruit Preparations / Fillings
Meat, Poultry, Fish, & Eggs
Potatoes, Pasta, & Rice
Sauces, Soups, & Dressings
Seasonings
Pet Food

By Region:

North America
Latin America
EMEAI
APAC

About Future Market Insights (FMI)

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Contact Us:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

Browse Other Reports: https://www.futuremarketinsights.com/reports

LinkedIn| Twitter| Blogs

Companion Animal Vaccines Market Insights on Emerging Scope Prophesy | FMI

Remarkable increase in the companion animal ownership and strong growth of development of the veterinary healthcare infrastructure collectively push the companion animal vaccines sales in global market.

Surpassing the revenues worth US$ 2.5 Bn in 2021, global Companion Animal Vaccines Market is projected to exhibit a robust CAGR during 2022 – 2029.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1427

Measurable rise in the zoonotic disease prevalence will remain a key factor fueling the demand for companion animal vaccines and drugs.

FDA approvals for novel and innovative companion animal vaccines continue to present potential growth opportunities to R&D of companion animal vaccines.

For instance, Zoetis received regulatory approval for ProHeart, used for prevention of heartworm diseases caused by Dirofilaria immitis in dogs.

Key Takeaways – Companion Animal Vaccines Market Study

Attenuated live vaccines currently account for more than a third of total market value, and will continue to witness a healthy CAGR through 2029. This demand growth is attributed to their improved effectivity and enhanced long-term preventive action.
North America is witnessing lucrative market growth compared to other regions attributed to increase in the adoption rate of companion animals, increase in veterinary healthcare expenditure, and increasing awareness about pet health.
Veterinary animal hospitals and clinics offering better service support for animal care are expected to have significant market share during the forecast period
As large number of people are in close contact with canine animals as a preference for companion animal, demand will be prominent among canine species.

Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-1427

Increasing R&D Investments to Widen Market Growth Prospects

Elanco, Ceva Sante Animale, Boehringer Ingelheim are among the leading market players in the companion animal vaccines market.

These manufacturers continue to dominate the market landscape of companion animal vaccines by investing heavily in R&D activities to develop and launch therapeutic vaccines for prevention and treatment of various animal diseases.

Surge in investment for R&D of vaccines, which inhibit the growth of antibiotic-resistant organisms boosts the animal vaccines market growth.

For instance, in August 2018, Elanco invested two-thirds of the budget for food‐animal unit to develop vaccines and reduce the use of antibiotics.

Moreover, rise in demand for animal vaccines led to the development of multiple new vaccines.

For instance, Cevac IBron a new vaccine was launched by Ceva in February 2017 for prevention against infectious bronchitis virus (IBV) in animals.

Know More About Companion Animal Vaccines Market Report

Future Market Insight brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2029.

The global companion animal vaccines is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provides compelling insights of the companion animal vaccines market on basis of product type (attenuated live vaccines, conjugated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, DNA vaccines, recombinant vaccines), species type (canine, avian, feline) and distribution channel (companion animal hospitals, companion animal hospitals, companion animal research institutes) across seven major regions.

Ask from the Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-1427

Segmented

Product

Attenuated Live Vaccines
Conjugate Vaccines
Inactivated Vaccines
Subunit Vaccines
Toxoid Vaccines
DNA Vaccines
Recombinant Vaccines

Species

Canine
Avian
Feline

Distribution Channel

Veterinary Clinics
Veterinary Hospitals
Veterinary Research Institutes
Retail Pharmacies

About Future Market Insights (FMI)

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Dengue Vaccines Market Demand: Strong Pipeline to Rapidly Surge Growth

Increasing prevalence of dengue fever throughout the Asia-Pacific region has propelled the demand for effectual medicines and vaccines to overcome this viral disease. While some pharmaceutical companies are focusing on development of a cure to dengue, the rate of dengue in Asia-Pacific region in expanding robustly. According a report published by Future Market Insights (FMI), Asia-Pacific region will dominate in the dengue vaccines market during the forecast period (2017-2027). The region is estimated to procure largest revenue share with expansion at 17.4% CAGR throughout the assessment period.

Get Sample of this Research Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1763

Geographic Overview

Latin America is likely to remain the second largest market for dengue vaccines and it will procure valuation nearly US$ 290 Mn by the end of forecast period. The report also forecasts that more and more pharmaceutical companies will be partaking in the expansion of dengue vaccines market in foreseeable period. A French drugmaker, Sanofi S.A. is actively participated in the market currently, while medicines are being formulated by leading players such as GlaxoSmithKline plc, Vabiotech, Merck & Co. Inc., Butantan Institute, Panacea Biotech Ltd, Takeda Pharmaceutical Company Limited, and Biological E. Limited.

The government institutes are expected to remain the largest end-user of the dengue vaccines, according to the report. Dengue vaccines sales across government institutes will generate revenues nearly US$ 650 Mn by the end of 2027. Further, hospitals will retain its dominance, exhibiting double-digit CAGR throughout the forecast period. Sales of the sole of the vaccines, Dengvaxia, manufactured by Sanofi is boosting the growth of the market presently. Additionally, the factors influencing the growth of the market profiled in the report are discussed below.

Key Highlights of Dengue Vaccines Market Report

Other than the burdening occurrence of dengue in some countries, the economic turmoil in Latin America is estimated to influence growth of the global market at macroeconomic level.
Live attenuated vaccines are also produced and developed economically, thereby consoling vaccines market and patients.
Low availability of optimum diagnostic systems and lack of skilled professionals have led to cases, where dengue fever is being treated as undistinguished febrile disease.
The global market of dengue vaccines is likely to secure an opportunistic revolution when companies are likely to able to successfully develop effective vaccines for all age groups.

Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-1763

Overall, the global dengue vaccines market, which is currently valued nearly US$ 250 Mn, will increase rapidly to reach over US$ 1,250 Mn in terms of revenues, by the end of 2027.

About Future Market Insights (FMI)

Contact:

Oral Controlled Release Drug Delivery Technology Market expected to See Incredible Growth By 2032

Future Market Insights (FMI), in its report, projects the global Oral Controlled Release Drug Delivery Technology Market to register an impressive expansion at 7.2% CAGR during the forecast period 2017 to 2027.

The market will surpass revenues worth US$ 20,000 Mn in 2017, and is further estimated to reach nearly US$ 50,000 Mn by 2027-end.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-4400

Oral Solid Dosage Manufacturers in North America Enabled to Achieve Significant Bioavailability

FMI’s report estimates North America to remain the largest market for oral controlled release drug delivery technology, with sales estimated to reach nearly US$ 20,000 Mn by 2027-end.

Being preferred route of drug administration by physicians, demand for oral controlled release drug delivery technology has been witnessing a surge by end-users in North America.

In addition, recent advancements in drug delivery have enabled oral solid dosage manufacturers in North America to achieve significant bioavailability through adoption of novel drug delivery platforms.

This is further expected to drive demand for oral controlled release drug delivery technology in the region.

However, increasing research activities related to biologic molecules, and their dominance in treating oncology conditions, coupled with government investments in these research activities are expected to impede the market growth in North America.

In addition, formulation challenges such as juncture of market expectations for once-daily dosing, and growth of controlled release tablets which impart abuse resistance, incurred in oral controlled release drug delivery technology are expected to further curb growth of the market in this region.

Request a Complete TOC of this Report with figures @ https://www.futuremarketinsights.com/toc/rep-gb-4400

New Chemical Entities Resulting from High Throughput Screening to Drive Market Growth in Western Europe

Western Europe will register the fastest expansion in the global oral controlled release drug delivery technology market.

This growth is primarily attributed to a slew of new chemical entities resulting from high throughput screening, which have low solubility and bioavailability.

This has further led manufacturers in this region to invest in drug delivery methods with better clinical outcome.

Owing to cost-sensitiveness in Western European countries, technologies enhancing bioavailability will remain preferred drug delivery system. These factors are expected to drive growth of the market in this region.

However, most of the pharmaceutical companies in Western Europe have complex supply chain, which is either under-utilised or inefficient.

Complexity of supply chain is attributed to low flexibility and cost-effectiveness. In addition, shortening of effective patent life along with patent cliffs is a major challenge for oral solid dosage forms in this region.

Factors such as these are estimated to hinder growth of the market in Western Europe.

Dissolution-Controlled Release System to Remain Sought-After among Drug Release Technologies in the Market

By drug release technology, dissolution-controlled release system will remain sought-after in the market, followed by diffusion-controlled release system.

Majority of generic formulations available are in tablet dosage form and follow dissolution-controlled release mechanism. Revenues from sales of dissolution-controlled release system will surpass US$ 10,000 Mn in 2017.

Demand for hydrodynamically-balanced drug delivery system will remain sluggish in the market.

Solid dosage forms of oral controlled release drug delivery technology are expected to remain dominant in the market, expanding at a high single-digit CAGR through 2027.

Sales of semisolid/liquid/suspensions dosage form segment will register a comparatively lower CAGR than that of solid dosage forms in the market through 2027.

Feel free to ask your queries@ https://www.futuremarketinsights.com/ask-question/rep-gb-4400

Key market players identified in FMI’s report include

AstraZeneca Plc.,

Bristol-Myers Squibb Company,

Sun Pharmaceuticals Industries Ltd,

Abbott Laboratories,

Merck & Co. Inc.,

Novartis AG,

Pfizer Inc.,

Mylan N.V.,

Sanofi,

Hoffman-La-Roche Ltd.,

Johnson & Johnson Services, Inc.,

Vectura Group plc.,

GlaxoSmithKline plc.

By Drug Release System

Diffusion Controlled Release System

Dissolution Controlled Release System

Osmotically Controlled Release System

Dissolution & Diffusion Controlled Release System

Ion Exchange Resins Controlled Release

Hydro-dynamically Balanced Drug Delivery System

Others

By Dosage Form

Solid Dosage Forms
Semisolid
Liquid/Suspension

About Future Market Insights (FMI)

Contact:

Farm Animal Drug Market | Cost Structure Analysis and Forecast to 2032 – By FMI

According to a latest study by Future Market Insights (FMI), the global Farm Animal Drug Market is projected to grow at over 6% CAGR during the period 2017-2027. Increased production of anti-infectives and penetration of parasiticides production in Latin America is expected to offer growth opportunities to players in this market.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-2402

The market will continue to be influenced by a slew of macro- and micro-economic factors. Demand for contamination-free meat and proteins and alliances between producers and meat companies will continue to offer growth opportunities.

North America Farm Animal Drugs Market

In North America, the U.S. will continue to be account for the leading revenue share. In 2017, the revenue share of the U.S. is anticipated to reach 58%; however, during the forecast period, it will lose slight market share to Canada. Demand for farm animal drugs in North America will continue to be influenced by growing consumption of fresh meat and regulation by the FDA to limit use of antibiotics on farm animals. FMI projects the North America farm animal drugs market to grow at 7% CAGR during the forecast period 2017-2027.

By product type, anti-infective drugs and parasiticides (endo-parasiticides, ecto-parasiticides, and endectocides). Anti-infectives are not only the largest but also the fastest-growing segment product type segment. By 2027, the anti-infective product type segment is projected to grow at nearly 9% CAGR. By animal type, poultry is the largest segment in North America, whereas ruminants and swine hold significant revenue share.

FMI also offers market forecast and analysis on the basis of route of administration. The oral route of administering drugs remains the most prominent in North America, with revenues projected to grow at over 7% CAGR. The parenteral drug segment, on the other hand, is anticipated to grow at nearly 9% CAGR through 2027.

By distribution channel, veterinary hospitals are the largest segment in North America, accounting for nearly US$ 2 billion in revenues in 2017. This segment is projected to grow at nearly 8% through 2027.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-2402

Western Europe Farm Animal Drugs Market

U.K. remains the largest market for farm animal drugs in Western Europe. The country accounts for over 40% revenue share of the market. FMI projects U.K. to remain the largest market for farm animal drugs in Western Europe throughout the forecast period. Germany and France are the other leading markets for farm animal drugs in Western Europe. Overall, the Western Europe farm animal drugs market is projected to reach US$ 2.83 billion revenues in 2027.

The key factors fuelling demand for farm animal drugs in Western Europe include focus on preventive measures against zoonotic diseases. Use of certain drugs for pain management is also a growing opportunity for manufacturers. As is the case in North America, the anti-infective product type segment is projected to grow at over 6% CAGR through 2027.

In addition to North America and Western Europe, the report also offers market forecast and analysis on Asia Pacific excluding Japan, Middle East & Africa, Latin America, and Japan.

Competitive Landscape

Key companies profiled in the report are Bayer AG, Boehringer Ingelheim GmbH, Zoetis, Inc., Ceva Santé Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health (Sub. Eli Lilly), Merck Animal Health, Virbac SA, Vetoquinol SA, Intas Animal Health, Alembic Animal Health, Sequent Scientific, Hester Biosciences, Ashish Life Sciences, Ouro Fino Saude Animal (Ourofino), Zydus Animal Health (Sub. Cadila Healthcare Ltd), Phibro Animal Health Corporation, Nippon Zenyaku Kogyo Co., Ltd, Norbrook, Kyoritsu Seiyaku Corporation.

Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-2402

Market segmentation

A good market segmentation always covers the vitals in that particular market to arrive at important decisions. In the case of the farm animal drugs market, an all-inclusive research segmentation can be seen.

Product Type

Anti-Infective
Parasiticides
- Endo-parasiticides
- Ecto-parasiticides
- Endectocides
Anti-inflammatory
Anesthetics
Analgesics
Hormones and related products
Others

Animal Type

Livestock Animals
- Ruminants
- Swine
- Poultry
Equine

Route of Administration

Oral
Parenteral
Topical
Others

Distribution Channel

Veterinary Hospitals
Veterinary Clinics
Pharmacies and Drug Stores
Others

About Future Market Insights (FMI)

Contact:

Biopharmaceutical Contract Manufacturing Positioning and Growing Market Share Worldwide

Global Biopharmaceutical Contract Manufacturing Market was estimated to be worth roughly US$ 8.4 billion in 2021 and is expected to grow at a CAGR of 10.5% to reach US$ 18.7 billion by 2029.

Reduced overall time to market investment in new drugs, access to expensive technologies, and greater flexibility are some advantages offered by biopharmaceutical manufacturing companies. On the back of these factors, several large companies have outsourced their biopharmaceutical manufacturing operations. Biopharmaceutical contract manufacturing is highly preferred among biopharmaceutical companies with limited in-house production capacity.

Get a Sample PDF: https://www.futuremarketinsights.com/reports/sample/rep-gb-2982

Pharmaceutical companies mainly focus on core areas of competence, and hence, do not prefer to take financial risks in the event of formulating the final dose of medicines. This is anticipated to accelerate the growth of the global biopharmaceutical contract manufacturing market during forecast period, estimated to be valued at US$ 18.7 Bn by 2029.

Key Market Segments Covered in Biopharmaceutical Contract Manufacturing Industry Research:

By Platform Type:

Mammalian Based
Microbial Based

By Product Type:

Monoclonal Antibodies
Recombinant Protein
Vaccine
Insulin
Growth factor
Interferons
Others

By Application Type:

Clinical
Commercial

By Therapeutic Area Type:

Autoimmune Diseases
Oncology
Metabolic Diseases
Ophthalmology
Cardiovascular Diseases
Infectious Diseases
Neurology
Respiratory Disorders
Others

By Region:

North America
Latin America
Western Europe
Eastern Europe
APEJ
Japan
Middle East and Africa (MEA)

Ask to Analyst: https://www.futuremarketinsights.com/ask-question/rep-gb-2982

Regional Insights:

The U.S. dominates the North American region with a total market share of 91.0% in 2021 and is projected to continue experiencing high growth throughout the forecast period.

Germany is set to exhibit a CAGR of over 11.5% in the European biopharmaceutical contract manufacturing market during the forecast period. In this region, the next generation therapy market is believed to be driven by biological treatment options compared to the pharmaceutical option.

China holds 34.8% share in the East Asia market in 2021 and is projected to increase at a CAGR rate of 13.5% during the forecast period. The growth of the biopharmaceutical contract manufacturing market in the country is growing because, most of the pharma and biopharma companies are focusing to capitalize on the growth.

Asia Pacific is gaining attention among manufacturers for biologics production at reduced manufacturing cost. Emerging regions offering greater profit margins are major focus points for biopharmaceutical contract manufacturing, globally.”

Key Takeaways of Biopharmaceutical Contract Manufacturing Market Study

Although microbial-based platforms are abundantly used for the production of pharmaceuticals, mammalian-based cell culture is expected to gain traction during the forecast period, owing to higher efficiency and increasing demand.
In terms of product type, monoclonal antibodies currently hold a larger share of the biopharmaceutical contract manufacturing market, due to their superior efficacy as well as increasing adoption for the treatment of chronic diseases.
North America is anticipated to be the most lucrative region in the global biopharmaceutical contract manufacturing market, offering growth opportunities to market players.
The commercial application of biopharmaceutical contract manufacturing is expected to contribute a higher share as compared to clinical application by the end of 2029.

Buy this Report Now: https://www.futuremarketinsights.com/checkout/2982

Key Market Players:

Catalent Inc.
Lonza Group Ag
Patheon N.V. (Thermo Fisher Scientific Inc.)
Abzena Plc.
Sandoz International GmbH (Novartis AG)
Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
Baxter Pharmaceutical Solutions LLC (Baxter Inc.)
AbbVie Contract Manufacturing (AbbVie Inc.)
Samsung Biologics Co. Ltd.
ProBioGen AG
Pfizer Centre Source Ltd (Pfizer Inc.)
Novasep
Biomeva GmbH
Kbi Biopharma Inc
Rentschler Biotechnologie GmbH
Ajinomoto Althea Inc. (Ajinomoto Co., Inc.)

About Future Market Insights (FMI)

Contact:

With Adoption in Developing Economies, the Molecular Imaging Market Will Reach New Heights

The global Molecular Imaging Market is anticipated to value at US$ 7.3 Billion while expanding at a CAGR of 5.41% during the forecast period of 2022-2032. The growth of the market can be attributed to the increasing incidences of chronic illness across the globe.

Increasing demand for early detection and cost-effective diagnosis of chronic diseases along with the rising geriatric population across the globe are likely to fuel demand for the molecular imaging system. The advent of modern devices and developing healthcare infrastructure in evolving economies are some of the salient factors escalating market growth.

Request a Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-724

The increasing prevalence of chronic diseases like cancer and other genetic illness are expected to propel the demand for an efficient and early disease diagnosis, which is projected to benefit the global molecular imaging market during the forecast period. Increasing adoption of molecular imaging for new applications, ongoing development and innovation in molecular imaging technologies, and developing economies are likely to provide significant opportunities for growth in the market in the coming time.

The launch of AI-based devices is projected to augment the market size in the coming time. For instance, in May 2020, Fujifilm Corporation launched AI-based technology for lung nodule detection. This technology is used to detect pulmonary nodules in chest CT scans to aid in lung cancer detection. In another instance, in November 2020, Canon Medical Systems Corporation launched One-Beat Spectral Cardiac CT, with rapid kVp switching and deep learning spectral reconstruction to acquire whole-heart spectral images in one beat. Thus, the launch of advanced products is anticipated to benefit the industry during the forecast period.

The increasing application of AI-based diagnostic equipment for the rapid detection of illnesses is anticipated to act as a significant opportunity for the global molecular imaging market during the forecast period. Players in the market are introducing AI-based equipment which will help the market in fetching significant dividends. In 2019, Siemens Healthineers introduced an ultrasound system, Acuson Redwood, which provides an imaging solution for clinical departments including cardiology, radiology, and gynecology.

However, high expenses associated with advanced molecular imaging system is projected to hamper the market growth during the forecast period. The presence of unfavorable reimbursements and lack of expertise in developing countries can hinder the market growth.

Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-724

Key Takeaways from the Market Study:

The global molecular imaging market is expected to secure US$ 4.309 Billion in 2022.
In Europe, the molecular imaging market is expected to display a CAGR of 4% during the forecast period.
In 2021, the hospital segment is projected to have secured 46.5% of the global revenue.
In APAC, the molecular imaging market is expected to display a CAGR of 6% during the forecast period.
In 2021, the molecular imaging market in North America is expected to have claimed 33% of the global revenue.

“Deployment of modern technologies in the healthcare sector and growing demand for early detection of chronic illness are likely to propel the demand for efficient molecular imaging equipment which will benefit the market during the forecast period,” says an FMI analyst.

Competition Analysis

Key players in the global molecular imaging market include Hermes Medical Solutions, Bruker Corporation, GE Company, Fujifilm Holdings Corp., Siemens AG, Koninklijke Philips N.V., and Toshiba Medical System Corp.

Recent Developments in the Market:

In September 2021, Hermes Medical Solutions and Isotopia Molecular Imaging announced a new collaboration with Isotopia to raise awareness and co-promote the benefits of dosimetry, personalized medicine, and radiopharmaceutical therapy.
In February 2021, Royal Philips announced the acquisition of BioTelemetry, a US-based player that provides remote cardiac diagnostics and monitoring. The acquisition of BioTelemetry is a strong fit with Philips’ cardiac care portfolio, and its strategy to transform the delivery of care along the health continuum with integrated solutions.

Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-724

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global molecular imaging market, presenting a historical analysis from 2017 to 2021 and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of Modality (Positron Emission Tomography (PET), Positron Emission Tomography- Computed Tomography (PET-CT), Positron Emission Tomography- Magnetic Resonance (PET-MR), Single Photon Emission Computed Tomography (SPECT), Software, Magnetic Resonance, Molecular Ultrasound Imaging), by Application (Cardiology, Oncology, Gastrointestinal Disorders, Neurology Disorders, Others), by End User (Hospitals, Ambulatory Surgical Centres, Diagnostic Centres), & Region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America).

About Future Market Insights (FMI)

Contact:

Neonatal Phototherapy Devices Market Detail Analysis of Current and Future Projection 2022-2027

The World Health Organization estimated in 2015 that 4/5th of preterm infants developed jaundice. Preterm birth rates can be as high as 7% in developed countries and are even higher in developing ones. Babies with neonatal jaundice are far more likely to develop hyperbilirubinemia that can lead to neurological damage or even premature death.

Get a Sample of this Research Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-5064

The National Institute of Health journal estimated that healthcare cost linked to preterm American births in terms of lost efficiency and medical expenditure were more than US$ 26 billion in 2005 itself. APAC and Africa had the unfortunate distinction of accounting for more than 80% of all preterm births in 2005, making infants there vulnerable to neonatal jaundice. Therefore, neonatal phototherapy treatment is the need of the hour.

Technological advancements in monitoring and phototherapy devices

Rapid technological innovations are predicted to favour companies investing in user-friendly control panel phototherapy devices and blue spectrum radiation sources. Key stakeholders are working on LED radiation sources as they can optimally control radiation intensity and have consume a minimal amount of power. Companies in the neonatal phototherapy devices market are focusing on devices with a peak wavelength of 460 nm and which can be mounted on an incubator or a warmer to avoid infrared and ultraviolet radiation. The primary drivers of growth in the neonatal phototherapy devices market are the high frequency of neonatal jaundice, rising demand for effective neonatal jaundice treatment and management, and a greater awareness of the existence of such procedures.

Home-based phototherapy actively promoted to create huge opportunities

The largest end-user in the neonatal phototherapy devices market is undoubtedly hospitals and NICU’s. However, the high treatment cost and lack of adequate phototherapy units at the vast majority of neonatal phototherapy centres have assisted the growth of home-based phototherapy units. Home-based phototherapy units have several advantages such as reduced patient hassle, transportation cost, and hospital waiting time. Furthermore, home-based phototherapy reduces both direct and indirect healthcare costs and improves the mother-infant bonding. An article published in the U.S. National Library of Medicine stated that approx. US$ 18,000 was saved by a little over 60 infants in their homes as opposed to hospitals and there were no reported side-effects.

Ask an Analyst@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-5064

Product differentiation a challenge in the neonatal phototherapy devices market

The uptake of neonatal phototherapy devices is minimal in low and medium income countries. Most revenue in the neonatal phototherapy devices market is generated in developed economies, their low birth rates notwithstanding. The North America neonatal phototherapy devices market is poised to grow to more than US$ 36 million in 2027 with the U.S alone approaching US$ 35 million. The main reason for this is the lack of product development in the neonatal phototherapy devices market. There have been several cases where neonatal phototherapy devices have failed and been recalled by the FDA, hampering revenue growth during the forecast period. For e.g. – In December 2016, the NeoBlue Blanket LED Phototherapy System was recalled by the FDA because of device degradation following the melting of its fibre optic cable.

High prices stifle adoption in the neonatal phototherapy devices market

Neonatal phototherapy devices are extremely expensive making affordability a critical issue in emerging economies as hospitals there often have limited funds and cannot afford to maintain such equipment. A Stanford study said that many hospitals in Nigeria and India were unable to source an average of six phototherapy bulbs that cost roughly US$ 15 per bulb as they needed to be replaced every four months. The APAC neonatal phototherapy devices market is anticipated to be valued at more than US$ 4 million by end 2027. Thus, companies need to try to make their neonatal phototherapy devices cost-effective and governmental support will also go a long way in boosting the prospects of the neonatal phototherapy devices market in emerging economies.

Buy Complete Report: https://www.futuremarketinsights.com/checkout/5064

About Future Market Insights (FMI)

Contact: